The FDA package insert for ruxolitinib warns against the concomitant use of CYP3A4 inhibitors during treatment of GVHD, myelofibrosis, and polycythemia vera (PCV), which may cause neutropenia and thrombocytopenia. This evidence concerns the gene CYP3A4 and graft versus host disease.